The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2024 | Using MRD to guide treatment decisions in myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the potential for using measurable residual disease (MRD) status to guide treatment decisions in clinical practice. Patients with multiple myeloma (MM) who achieve MRD-negativity may be able to discontinue treatment early and undergo a treatment-free interval. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Measurable residual disease testing has increasingly been applied in clinical trials and has started to be used in clinical practice. Myeloma is an incurable condition, but MRD testing can tell us how deep the remission is in a particular patient. So, where more treatments are becoming available for myeloma patients, if patients are minimal residual disease negative, then potentially some patients can be given a treatment-free interval...
Measurable residual disease testing has increasingly been applied in clinical trials and has started to be used in clinical practice. Myeloma is an incurable condition, but MRD testing can tell us how deep the remission is in a particular patient. So, where more treatments are becoming available for myeloma patients, if patients are minimal residual disease negative, then potentially some patients can be given a treatment-free interval. Alternatively, when patients are minimal residual disease positive consistently and they have been given a particular treatment and they are seen to be as a high-risk patient, then potentially in the future, we’ll be thinking about giving them a different treatment to convert them to MRD negativity. So, in clinical practice right now, most clinicians are starting to think about using minimal residual disease testing, particularly to discontinue therapy early on when patients are on continuous therapy.
Read more...
